2',5'-乙酰乙酰二甲基苯胺 | 3785-25-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2',5'-乙酰乙酰二甲基苯胺
• 英文名称: acetoacet-p-xylidide
• 英文别名: N-(2,5-dimethylphenyl)-3-oxobutanamide；Acetessigsaeure-<2,5-dimethyl-anilid>；acetoacetic acid-(2,5-dimethyl-anilide)；Acetessigsaeure-(2,5-dimethyl-anilid)
• CAS: 3785-25-9
• 化学式: C₁₂H₁₅NO₂
• mdl: MFCD00026249
• 分子量: 205.257
• InChiKey: RYPZJWMUMBWFHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  2',5'-乙酰乙酰二甲基苯胺 在 N-氯代丁二酰亚胺 、 C₂₀H₂₇N₃O₂S 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以95%的产率得到2,2-dichloro-N-(2,5-dimethylphenyl)acetamide
  参考文献：
  名称：

  Zwitterion-Catalyzed Deacylative Dihalogenation of β-Oxo Amides

  摘要：

  alpha,alpha-Dihalo-N-arylacetamides are commonly used as intermediates in various organic reactions. In the study described here, a catalytic synthesis of alpha,alpha-dihalo-N-arylacetamides from beta-oxo amides was developed using zwitterionic catalysts and N-halosuccinimides as the halogen sources. The corresponding alpha,alpha-dihalo-N-arylacetamides were obtained in good to excellent yields, and no aromatic halogenated side products were detected. The reaction conditions were mild, and no strong base or acid was required.

  DOI：

  10.1021/acs.orglett.0c02701
• 作为产物：
  描述：

  2,5-二甲基苯胺 、 乙酰乙酸乙酯 在 正己烷 作用下， 反应 0.08h， 生成 2',5'-乙酰乙酰二甲基苯胺
  参考文献：
  名称：

  Condensed Ring Pyridine Compounds As Subtype-Selective Modulators Of Sphingosine-1-Phosphate-2 (S1P2) Receptors

  摘要：

  本发明提供了由式I表示的化合物，其中每个化合物可能具有鞘氨醇-1-磷酸受体激动剂和/或拮抗剂生物活性，这些化合物选自以下组中：其中A、B、C、D、X、Y、Z和R3在规范中定义。所述化合物用于治疗哺乳动物的疾病或病况，所述哺乳动物选自以下组中：眼部疾病；系统性血管屏障相关疾病；过敏和其他炎症性疾病；心脏疾病或病况；纤维化；疼痛和伤口。

  公开号：

  US20130296361A1

文献信息

• The preparation of 4-oxo-<i>N</i>-aryl-4<i>H</i>-1-benzopyran-2-acetamides by the condensation/cyclization of trilithiated acetoacetanilides with lithiated methyl salicylates
  作者：Douglas R. Hurst、Kristen L. French、April J. Angel、Angela R. Williams、Mary E. Rampey、Tina S. Guion、Kam W. Chan、Camille M. Kassis、Shannon L. Studer Martinez、Charles F. Beam

  DOI：10.1002/jhet.5570350622

  日期：1998.11

  Several acetoacetanilides were trilithiated in excess lithium diisopropylamide, and the resulting polylithiated intermediates were regioselectively condensed with lithiated methyl salicylates followed by acid cyclization to substituted 4-oxo-N-aryl-4H-1-benzopyran-2-acetamides (benzopyranone-2-acetamides).

  在过量的二异丙基氨基锂中将数个乙酰乙酰苯胺三锂化，然后将所得的多锂化中间体与锂化的水杨酸甲酯区域选择性地缩合，然后酸环化成取代的4-氧代-N-芳基-4 H -1-苯并吡喃-2-乙酰胺（苯并吡喃酮-2-乙酰胺）。
• A Concise [3 + 3] Heteroaromatization Synthetic Strategy Afford Dicarboxamide Functionalized Novel Pyrazolo[1,5-<i>a</i>]Pyrimidines
  作者：Anilkumar S. Patel、Naval P. Kapuriya、Yogesh T. Naliapara

  DOI：10.1002/jhet.2860

  日期：2017.9

  A concise and effective approach to dicarboxamide functionalized novel pyrazolo[1,5‐a]pyrimidine has been developed. The method involves [3 + 3] hetroaromatization of oxoketene dithioacetals (16a–x) with 5‐amino‐N‐cyclohexyl‐3‐(methylthio)‐1H‐pyrazole‐4‐carboxamide (12) in the presence of K2CO3. This method has advantages of excellent yields, operational simplicity, and avoidance of hazardous base

  已经开发出一种简洁有效的方法将二甲酰胺官能化的新型吡唑并[1,5- a ]嘧啶。该方法涉及在存在K 2 CO的情况下，用5-氨基-N-环己基-3-（甲硫基）-1H-吡唑-4-羧酰胺[ 12 +3]氧化氧杂环丁二硫缩醛（16a–x）的芳香化。3。该方法的优点是产率高，操作简单并且避免了诸如哌啶的有害碱。
• Preparation of <i>N</i>-aryl-4-oxo-4<i>H</i>-1-benzothiopyran-2-acetamides from trilithiated acetoacetanilides and lithiated methyl thiosalicylate
  作者：April J Angel、Anne E Finefrock、Kristen L French、Douglas R Hurst、Angela R Williams、Mary E Rampey、Shannon L Studer-Martinez、Charles F Beam

  DOI：10.1139/v98-216

  日期：1999.1.1

  Acetoacetanilide and substituted acetoacetanilides were trilithiated in excess lithium diisopropylamide, and the polylithiated intermediates were regioselectively condensed with lithiated methyl thiosalicylate, followed by acid cyclization to afford substituted N-aryl-4-oxo-4H-1-benzothiopyran-2-acetamides (thiochromone-2-acetamides).Key words: thiochromones, strong-base multiple anion synthesis, Claisen-type condensation.

  乙酰基苯甲酰胺和取代的乙酰基苯甲酰胺在过量的异丙胺锂中三锂化，然后多锂化中间体与锂化的甲基硫代水杨酸酯选择性地缩合，随后经过酸环化反应得到取代的N-芳基-4-氧代-4H-1-苯并硫杂吡喃-2-乙酰胺（硫代色酮-2-乙酰胺）。关键词：硫代色酮，强碱多阴离子合成，Claisen型缩合。
• Synthesis and QSAR Studies of 4-Substituted phenyl-2,6-dimethyl-3, 5-bis-N-(substituted phenyl)carbamoyl-1,4-dihydropyridines as potential antitubercular agents
  作者：Bhavik Desai、Dinesh Sureja、Yogesh Naliapara、Anamik Shah、Anil K Saxena

  DOI：10.1016/s0968-0896(01)00141-9

  日期：2001.8

  Synthesis and QSAR studies of the title compounds have resulted in the identification of structural and physicochemical parameters (MR, sigma(o), sigma(m), sigma(p)) contributing to antitubercular activity. Among these, carbamoyl phenyl ring substituted at 3 and 4 position with NO(2) group or 2 position with Cl or OCH(3) group shows >90% inhibition against H(37)Rnu comparable to other substituted phenyls

  标题化合物的合成和QSAR研究已鉴定出有助于抗结核活性的结构和物理化学参数（MR，sigma（o），sigma（m），sigma（p））。其中，在3和4位被NO（2）取代或在2位被Cl或OCH（3）取代的氨基甲酰基苯环与其他取代的苯基相比，对H（37）Rnu的抑制作用大于90％。
• [EN] CONDENSED RING PYRIDINE COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-2 (S1P2) RECEPTORS<br/>[FR] COMPOSÉS PYRIDINES À NOYAUX CONDENSÉS COMME MODULATEURS SÉLECTIFS D'UN SOUS-TYPE DES RÉCEPTEURS DE LA SPHINGOSINE-1-PHOSPHATE-2 (S1P2)
  申请人：ALLERGAN INC

  公开号：WO2011041287A1

  公开（公告）日：2011-04-07

  The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity, wherein these compounds selected from the group consisting of wherein A, B, C, D, X, Y, Z and R3 are defined in the specification. Said compounds are useful for treating a disease or condition of a mammal selected from the group consisting of ocular diseases; systemic vascular barrier related diseases; allergies and other inflammatory diseases; cardiac diseases or conditions; fibrosis; pain and wounds.

  该发明提供了由公式I表示的化合物，其中每个化合物可能具有鞘氨醇-1-磷酸受体激动剂和/或拮抗剂生物活性，这些化合物选自由A、B、C、D、X、Y、Z和R3定义的组成的组中。所述化合物适用于治疗从眼部疾病；全身血管屏障相关疾病；过敏和其他炎症性疾病；心脏疾病或症状；纤维化；疼痛和伤口中选择的哺乳动物的疾病或症状。